February 26, 2020 Go or no go? Ozanimod and Fintepla await FDA verdicts Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.
July 12, 2017 Venture financing still positive but big rounds less common The trend for VCs to pile in to bigger, later rounds might just be weakening.